Precigen, Inc. (PGEN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Precigen, Inc. (PGEN) closed at USD 7.36 on 2026-10-14, a change of +81.3 % over the past year, with a market capitalization of USD 2.57B.

Precigen, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Precigen, Inc. key figures

Previous close

USD 7.36 (2026-10-14)

1-year change

+81.3 %

Market cap

USD 2.57B

Enterprise value

USD 2.64B

P/E ratio (trailing)

-7.05

P/E ratio (forward)

-32.71

EPS (trailing)

-1.02

EPS (forward)

-0.22

PEG ratio

n/a

Price to book

58.98

Revenue growth

6,322.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.24

Employees

160

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Precigen, Inc.

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Precigen, Inc. and compare it with other stocks.